| Drug Name |
Cefadroxil hemihydrate |
| Drug ID |
BADD_D00380 |
| Description |
Long-acting, broad-spectrum, water-soluble, cephalexin derivative. |
| Indications and Usage |
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes |
| Marketing Status |
approved; vet_approved; withdrawn |
| ATC Code |
J01DB05 |
| DrugBank ID |
DB01140
|
| KEGG ID |
D02353; D00257
|
| MeSH ID |
D002434
|
| PubChem ID |
67173987
|
| TTD Drug ID |
D0X9ZC
|
| NDC Product Code |
16714-390; 43063-553; 57237-096; 57237-098; 63629-7987; 63629-8253; 66267-045; 68180-180; 68788-8479; 65862-359; 16714-389; 72189-445; 80425-0198; 65862-085; 50090-6050; 63629-7988; 68180-182; 68071-5234; 16714-388; 45865-503; 63187-883; 68071-2752; 70518-2538; 50090-0580; 57237-097; 68788-7484; 68788-8261; 0093-3196; 0093-4059; 43063-595; 65862-083; 65862-084; 70518-3580; 72189-103; 50090-6356; 55289-589; 68180-181; 67296-1038; 68071-2938; 53002-2290 |
| UNII |
J9CMF6461M
|
| Synonyms |
Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate |
